Plus Therapeutics, Inc.
Plus Therapeutics, Inc., headquartered in the United States, is a pioneering biotechnology company focused on developing innovative therapies for cancer treatment. Founded in 2016, the company has made significant strides in the field of radiopharmaceuticals, particularly with its lead product, Rhenium-186 NanoLiposome, designed for targeted cancer therapy. With a commitment to advancing treatment options, Plus Therapeutics operates primarily in the oncology sector, leveraging its proprietary technology to enhance the delivery of therapeutic agents. The company has garnered attention for its unique approach to radiotherapy, positioning itself as a leader in the development of next-generation cancer treatments. Notable achievements include successful clinical trials that underscore its potential to improve patient outcomes in challenging cancer types.
DitchCarbon Score
How does Plus Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Plus Therapeutics, Inc.'s score of 18 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Plus Therapeutics, Inc.'s reported carbon emissions
Plus Therapeutics, Inc., headquartered in the US, currently does not have any publicly available carbon emissions data for the most recent year, nor do they have specified reduction targets or climate pledges. As a result, there is no quantifiable information regarding their Scope 1, 2, or 3 emissions. In the absence of specific emissions data, it is important to note that many companies in the biopharmaceutical sector are increasingly focusing on sustainability and climate commitments. This often includes initiatives aimed at reducing their carbon footprint and enhancing environmental responsibility. However, without concrete data or commitments from Plus Therapeutics, it is unclear how they align with industry standards or climate action goals. For stakeholders and environmentally conscious investors, monitoring Plus Therapeutics' future disclosures on emissions and sustainability initiatives will be essential to assess their commitment to climate action.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Plus Therapeutics, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
